Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 3,979 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathophysiology Clear all
Suspended Not applicable Interventional Accepts healthy volunteers

Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults

NCT06077292
View directory record Official record
Conditions
Cannabis Use, THC, Marijuana Use, Cognitive Impairment, THC Vaping
Interventions
15% THC Potency Reduction, 35% THC Potency Reduction
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 25 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 10, 2026, 2:15 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)

NCT05459753
View directory record Official record
Conditions
Parkinson Disease, Progressive Supranuclear Palsy
Interventions
(18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET, Dihydrotetrabenazine (DTBZ) PET
Radiation
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 10, 2026, 2:15 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Differing Levels of Hypoglycemia

NCT02445781
View directory record Official record
Conditions
Hypoglycemia
Interventions
Glucose clamp
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2026 · Synced Nov 10, 2026, 2:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

5-Cog Battery for Detecting Cognitive Impairment and Dementia

NCT03816644
View directory record Official record
Conditions
Dementia, Cognitive Impairment, Mild Cognitive Impairment, Neurocognitive Disorders
Interventions
5-Cog, Health Literacy & Grip Assessment
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
1,201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Nov 10, 2026, 2:15 AM EST
Completed Phase 4 Interventional Results available

A Study in Erectile Dysfunction

NCT01130532
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Huntsville, Alabama • Lancaster, California • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Nov 10, 2026, 2:15 AM EST
Completed Not applicable Interventional

Study of Bone Growth in the Sacroiliac Joint After Minimally Invasive Surgery With Titanium Implants

NCT03122899
View directory record Official record
Conditions
Sacroiliac Dysfunction
Interventions
SIJ fusion with iFuse-3D
Device
Lead sponsor
SI-BONE, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
11
States / cities
Long Beach, California • Aurora, Colorado • Johnstown, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Nov 10, 2026, 2:15 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Test of Neural Inertia in Humans With Xenon

NCT02768727
View directory record Official record
Conditions
Neurocognitive Dysfunction
Interventions
Xenon
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
20 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 10, 2026, 2:15 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease

NCT01491022
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Ampyra first, then Placebo, placebo first, then Ampyra
Drug
Lead sponsor
University of Miami
Other
Eligibility
45 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Nov 10, 2026, 2:15 AM EST
Completed Phase 1 Interventional

Endothelial Cell Dysfunction in Pulmonary Hypertension

NCT00098072
View directory record Official record
Conditions
Secondary Pulmonary Arterial Hypertension
Interventions
Heart Catheterization
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 10, 2026, 2:15 AM EST
Completed No phase listed Observational

Blood Brain Barrier Dysfunction and Postoperative Neurocognitive Disorders

NCT04566562
View directory record Official record
Conditions
Neurocognitive Disorders, Postoperative Cognitive Dysfunction
Interventions
Brain Imaging, Cognitive Testing, Blood Biomarkers
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Nov 10, 2026, 2:15 AM EST
Completed Early Phase 1 Interventional

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

NCT02517502
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
DHA, Placebo
Drug
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Decatur, Illinois • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Nov 10, 2026, 2:15 AM EST
Completed Not applicable Interventional

A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence

NCT05735223
View directory record Official record
Conditions
Prostate Adenocarcinoma, Incontinence Stress, Erectile Dysfunction Following Radical Prostatectomy
Interventions
Maximal urethral length preservation technique of robot assisted radical prostatectomy (RALP).
Procedure
Lead sponsor
Larkin Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Nov 10, 2026, 2:15 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Nov 10, 2026, 2:15 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance

NCT03112902
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Nov 10, 2026, 2:15 AM EST
Completed Phase 1 Interventional

Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant

NCT00092937
View directory record Official record
Conditions
Granulomatous Disease, Chronic
Interventions
Busulfan
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 10, 2026, 2:15 AM EST
Active, not recruiting Not applicable Interventional

Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction

NCT05223322
View directory record Official record
Conditions
Breast Cancer
Interventions
Taking Charge during Treatment (TCT) Intervention
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 10, 2026, 2:15 AM EST
Recruiting Phase 2 Interventional

Ca-Mg Butyrate in Gulf War Illness

NCT05367245
View directory record Official record
Conditions
Gulf War Illness, Chronic Fatigue, Neurocognitive Dysfunction
Interventions
Cal-Mag Butyrate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Long Beach, California • Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 10, 2026, 2:15 AM EST
Completed Phase 2 Interventional Results available

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

NCT03518203
View directory record Official record
Conditions
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
Interventions
Eculizumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 10, 2026, 2:15 AM EST
Completed Phase 3 Interventional Results available

Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type

NCT03721705
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia, Cognitive Decline, Dementia, Alzheimer Type
Interventions
Renew NCP-5
Device
Lead sponsor
Renew Research, LLC
Other
Eligibility
55 Years to 85 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Irvine, California • Lady Lake, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Nov 10, 2026, 2:15 AM EST
Recruiting Phase 4 Interventional

Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study

NCT05612594
View directory record Official record
Conditions
Sleep Apnea
Interventions
Bexagliflozin 20 mg, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 10, 2026, 2:15 AM EST
Completed No phase listed Observational

Chemotherapy-Induced Cognitive Impairment

NCT01578083
View directory record Official record
Conditions
Cognitive Symptoms
Interventions
Not listed
Lead sponsor
Jay F. Piccirillo, MD
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Nov 10, 2026, 2:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Parasacral Transcutaneous Electrical Nerve Stimulation PTENS for Voiding Dysfunction in Peds Population

NCT04570605
View directory record Official record
Conditions
Overactive Bladder, Voiding Disorders, Incontinence, Urinary
Interventions
parasacral transcutaneous electrical nerve stimulation (PTENS), Standard Urotherapy
Device · Other
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Nov 10, 2026, 2:15 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Randomized Study of TransAeris® System in Cardiac Surgery Patients at Risk of Prolonged Mechanical Ventilation

NCT04899856
View directory record Official record
Conditions
Ventilator Induced Diaphragm Dysfunction
Interventions
TransAeris
Device
Lead sponsor
Synapse Biomedical
Industry
Eligibility
22 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Nov 10, 2026, 2:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

NCT05478603
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
PF-07081532
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Nov 10, 2026, 2:15 AM EST